CRL241220C160000
- 0.00
- 0.000.00%
Charles River Newsroom
CRO Services Market Report 2024, With Key Player Profiles for Medpace, ICON, IQVIA, Syneos Health, Parexel, Charles River Laboratories, Thermofisher Scientific, Pharmaron Beijing and Altasciences
Morgan Stanley Maintains Charles River(CRL.US) With Hold Rating, Maintains Target Price $220
Morgan Stanley Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $220
Cautious Hold Rating for Charles River Labs Amid Stable Projections and Slight Price Target Adjustment
0.2% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Charles River Laboratories International (NYSE:CRL) Shareholders Over That Period
Express News | Charles River Laboratories International Inc - Credit Agreement Reduces Revolving Commitments to $2 Billion
Charles River Labs Is Maintained at Neutral by B of A Securities
Charles River Analyst Ratings
Express News | Charles River Laboratories International Inc : BofA Global Research Cuts Price Objective to $210 From $220
BofA Securities Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $210
Zacks.com Featured Highlights Include InterDigital, ResMed, Greenbrier Companies, Charles River Associates and Kontoor Brands
5 Solid Dividend Growth Stocks to Buy Now
Here's Why Charles River Associates Stock Is a Great Pick
The WuXi system welcomes a bullish trend! What is the next catalyst?
Many institutions have indicated that this may be a critical juncture for the healthcare sector.
Express News | China Securities Co.,Ltd.: Still bullish on the development potential and growth space of the CXO sector in the long term.
17 Stocks With Rebounding Operating Margins – Goldman
CRL Stock to Gain From the Global Biotech Incubator Program Launch
Out-of-consensus Buy Ideas According to Goldman: CAG, TRIP, TDOC
Charles River Introduces Global Biotech Incubator Program
Charles River Laboratories to Present at Evercore ISI Investor Conference